Today, the CEO & President of Akebia Therapeutics, John P. Butler, exercised options of Akebia Therapeutics (NASDAQ: AKBA) for $47K.
This recent transaction increases John P. Butler’s holding in the company by 24.37% to a total of $5.09 million. Following John P. Butler’s last AKBA Buy transaction on January 23, 2017, the stock climbed by 0.7%.
See today’s analyst top recommended stocks >>
Based on Akebia Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $45.93 million and GAAP net loss of $23.42 million. In comparison, last year the company earned revenue of $28.52 million and had a GAAP net loss of $21.52 million. Currently, Akebia Therapeutics has an average volume of 677.5K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.00, reflecting a -54.3% downside. Starting in November 2017, AKBA received 16 Buy ratings in a row. 10 different firms, including BMO Capital and Brean Capital, currently also have a Buy rating on the stock.
John P. Butler’s trades have generated a -11.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
